Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1High Grade Cervical Intraepithelial Neoplasia 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Brentuximab Vedotin 27pembrolizumab 13Nivolumab 11Dacarbazine 8Vinblastine 7Doxorubicin 7Gemcitabine 6Bendamustine Hydrochloride 6plerixafor 5fludarabine 4Rituximab 4Granulocyte Colony-Stimulating Factor 4Cyclophosphamide 4Azacitidine 4abexinostat 3Melphalan 3Filgrastim 3Etoposide 3Busulfan 3Bleomycin 3umbralisib 2relatlimab 2pegfilgrastim 2mocetinostat 2itacitinib 2givinostat hydrochloride 2givinostat 2fludarabine phosphate 2durvalumab 2cc-486 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hodgkin Disease × Biological Products × Clear all
NCT03383965 2017-12-27

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Immune Cell, Inc.

Phase 1 Unknown
20 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡